BioCentury | Apr 3, 2006
Company News

Threshold management update

...regulatory affairs and quality, formerly VP of regulatory affairs and quality assurance and control at Anosys Inc....
BioCentury | Mar 21, 2005
Company News

Anosys, Chromos deal

...CHR signed a letter of intent to acquire Anosys for stock, warrants and convertible notes. Both...
...and convertible notes. Both companies develop compounds for cancer and infectious disease. CHR will issue Anosys...
...day before the deal was announced. CHR also will purchase a debenture from a single Anosys...
BioCentury | Feb 28, 2005
Company News

Anosys, Avidex deal

...T cell receptors to validate T cell antigen expression on Anosys' Dexosome cancer vaccine candidates. Anosys'...
...lead candidate has completed Phase I trials for melanoma and non-small cell lung cancer (NSCLC). Anosys Inc....
BioCentury | Sep 15, 2003
Company News

Anosys, Epimmune deal

...EPMN received an undisclosed milestone payment from Anosys under a 2001 deal in which Anosys non-exclusively...
...payment was triggered when Anosys filed an IND for a product containing the EPMN technology. Anosys Inc....
BioCentury | Aug 18, 2003
Company News

Anosys, Epimmune deal

...of the February merger announcement, the companies said the combination of EPMN's epitope technology and Anosys'...
...technology and IP around activating antigen-specific immune responses, particularly in the area of cancer vaccines. Anosys Inc....
BioCentury | Aug 12, 2003
Company News

Epimmune, Anosys merger terminated

...EPMN and Anosys (Menlo Park, Calif.) terminated their previously announced merger. EPMN said the companies concluded...
...of the February merger announcement, the companies said the combination of EPMN's epitope technology and Anosys'...
BioCentury | Feb 17, 2003
Company News

Epimmune, Anosys deal

...EPMN and cancer vaccine company Anosys said they will merge in an all stock transaction. The...
...in an all stock transaction. The combined company will bring together EPMN's epitope technology and Anosys'...
...pipeline will include EPMN's HIV-1090, which is in Phase I/II studies to treat HIV, and Anosys'...
BioCentury | Feb 13, 2003
Company News

Epimmune, Anosys to merge

...EPMN and cancer vaccine company Anosys (Menlo Park, Calif.) said they will merge in an all...
...in an all stock transaction. The combined company will bring together EPMN's epitope technology and Anosys'...
...pipeline will include EPMN's HIV-1090, which is in Phase I/II studies to treat HIV, and Anosys'...
BioCentury | Oct 28, 2002
Clinical News

Dexosome-based cancer vaccine: Phase I

...tumor antigens. Anosys said the vaccine was well tolerated and there was no serious toxicity. Anosys Inc....
BioCentury | Oct 28, 2002
Clinical News

Dexosome-based cancer vaccine: Phase II

...July a U.S. Phase II study of its dexosome-based cancer vaccine in 60 melanoma patients. Anosys Inc....
Items per page:
1 - 10 of 13
BioCentury | Apr 3, 2006
Company News

Threshold management update

...regulatory affairs and quality, formerly VP of regulatory affairs and quality assurance and control at Anosys Inc....
BioCentury | Mar 21, 2005
Company News

Anosys, Chromos deal

...CHR signed a letter of intent to acquire Anosys for stock, warrants and convertible notes. Both...
...and convertible notes. Both companies develop compounds for cancer and infectious disease. CHR will issue Anosys...
...day before the deal was announced. CHR also will purchase a debenture from a single Anosys...
BioCentury | Feb 28, 2005
Company News

Anosys, Avidex deal

...T cell receptors to validate T cell antigen expression on Anosys' Dexosome cancer vaccine candidates. Anosys'...
...lead candidate has completed Phase I trials for melanoma and non-small cell lung cancer (NSCLC). Anosys Inc....
BioCentury | Sep 15, 2003
Company News

Anosys, Epimmune deal

...EPMN received an undisclosed milestone payment from Anosys under a 2001 deal in which Anosys non-exclusively...
...payment was triggered when Anosys filed an IND for a product containing the EPMN technology. Anosys Inc....
BioCentury | Aug 18, 2003
Company News

Anosys, Epimmune deal

...of the February merger announcement, the companies said the combination of EPMN's epitope technology and Anosys'...
...technology and IP around activating antigen-specific immune responses, particularly in the area of cancer vaccines. Anosys Inc....
BioCentury | Aug 12, 2003
Company News

Epimmune, Anosys merger terminated

...EPMN and Anosys (Menlo Park, Calif.) terminated their previously announced merger. EPMN said the companies concluded...
...of the February merger announcement, the companies said the combination of EPMN's epitope technology and Anosys'...
BioCentury | Feb 17, 2003
Company News

Epimmune, Anosys deal

...EPMN and cancer vaccine company Anosys said they will merge in an all stock transaction. The...
...in an all stock transaction. The combined company will bring together EPMN's epitope technology and Anosys'...
...pipeline will include EPMN's HIV-1090, which is in Phase I/II studies to treat HIV, and Anosys'...
BioCentury | Feb 13, 2003
Company News

Epimmune, Anosys to merge

...EPMN and cancer vaccine company Anosys (Menlo Park, Calif.) said they will merge in an all...
...in an all stock transaction. The combined company will bring together EPMN's epitope technology and Anosys'...
...pipeline will include EPMN's HIV-1090, which is in Phase I/II studies to treat HIV, and Anosys'...
BioCentury | Oct 28, 2002
Clinical News

Dexosome-based cancer vaccine: Phase I

...tumor antigens. Anosys said the vaccine was well tolerated and there was no serious toxicity. Anosys Inc....
BioCentury | Oct 28, 2002
Clinical News

Dexosome-based cancer vaccine: Phase II

...July a U.S. Phase II study of its dexosome-based cancer vaccine in 60 melanoma patients. Anosys Inc....
Items per page:
1 - 10 of 13